Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.01.088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Yosuke Nagai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Diabetes Foundation, Suzuken Memorial Foundation, MSD Life Science Foundation, Public Interest Incorporated Foundation.
Abstract (Originalsprache)
The small GTPase Rho and its effector Rho-kinase (ROCK) are activated in the diabetic kidney, and recent studies decade have demonstrated that ROCK signaling is an integral pathway in the progression of diabetic kidney disease. We previously identified the distinct role of ROCK1, an isoform of ROCK, in fatty acid metabolism in diabetic glomeruli. However, the effect of pharmacological intervention for ROCK1 is not clear. In the present study, we show that the inhibition of ROCK1 by Y-27632 and fasudil restores fatty acid oxidation in the glomeruli. Mechanistically, these compounds optimize fatty acid utilization and redox balance in mesangial cells via AMPK phosphorylation and the subsequent induction of PGC-1α. A further in vivo study showed that the inhibition of ROCK1 suppressed the downregulation of the fatty acid oxidation-related gene expression in glomeruli and mitochondrial fragmentation in the mesangial cells of db/db mice. These observations indicate that ROCK1 could be a promising therapeutic target for diabetic kidney disease through a mechanism that improves glomerular fatty acid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Electronic address: matoba@jikei.ac.jp.
- Diabetic Neuropathy Project, Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
- Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka, Japan.
- Nomura Hospital, Tokyo, Japan.
Förderung
- Japan Diabetes Foundation
- Suzuken Memorial Foundation
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Takeda Science Foundation
- Uehara Memorial Foundation
- Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
- Japan Society for the Promotion of Science
Zitieren
APA
Nagai, Y., Matoba, K., Yako, H., Ohashi, S., Sekiguchi, K., Mitsuyoshi, E., Sango, K., Kawanami, D., Utsunomiya, K., & Nishimura, R. (2023). Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.01.088
Vancouver
Nagai Y, Matoba K, Yako H, Ohashi S, Sekiguchi K, Mitsuyoshi E, et al. Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.01.088
BibTeX
@article{Nagai2023,
author = {Nagai, Yosuke and Matoba, Keiichiro and Yako, Hideji and Ohashi, Shinji and Sekiguchi, Kensuke and Mitsuyoshi, Etsuko and Sango, Kazunori and Kawanami, Daiji and Utsunomiya, Kazunori and Nishimura, Rimei},
title = {Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.01.088}
}
EUVIMED